Volume 23: Issue 3 (Aug 2024): Acute Kidney Injury and Critical Care Nephrology

Patel A, Zhang C, Minacapelli CD, Gupta K, Catalano C, Li Y, et al.: Outcomes, mortality, and cost burden of acute kidney injury and hepatorenal syndrome in patients with cirrhosis. J Gastrointestin Liver Dis 32: 39–50, 2023 10.15403/jgld-4618 PubMed

• PubMed
Patel A, Zhang C, Minacapelli CD, Gupta K, Catalano C, Li Y, : Outcomes, mortality, and cost burden of acute kidney injury and hepatorenal syndrome in patients with cirrhosis. J Gastrointestin Liver Dis 32: 39–50, 2023 10.15403/jgld-4618 PubMed)| false
• Search Google Scholar
• Export Citation

Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, et al.: Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105: 229–236, 1993 10.1016/0016-5085(93)90031-7 PubMed

• PubMed
Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, : Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105: 229–236, 1993 10.1016/0016-5085(93)90031-7 PubMed)| false
• Search Google Scholar
• Export Citation

Kanduri SR, Velez JCQ: Kidney dysfunction in the setting of liver failure: Core curriculum 2024. Am J Kidney Dis 83: 386–401, 2024 10.1053/j.ajkd.2023.08.013 PubMed

• PubMed
Kanduri SR, Velez JCQ: Kidney dysfunction in the setting of liver failure: Core curriculum 2024. Am J Kidney Dis 83: 386–401, 2024 10.1053/j.ajkd.2023.08.013 PubMed)| false
• Search Google Scholar
• Export Citation

Patidar KR, Belcher JM, Regner KR, St Hillien SA, Simonetto DA, Asrani SK, from the HRS-HARMONY consortium, et al.: Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US. J Hepatol 79: 1408–1417, 2023 10.1016/j.jhep.2023.07.010 PubMed

• PubMed
Patidar KR, Belcher JM, Regner KR, St Hillien SA, Simonetto DA, Asrani SK, from the HRS-HARMONY consortium, : Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US. J Hepatol 79: 1408–1417, 2023 10.1016/j.jhep.2023.07.010 PubMed)| false
• Search Google Scholar
• Export Citation

Gambino C, Piano S, Stenico M, Tonon M, Brocca A, Calvino V, et al.: Diagnostic and prognostic performance of urinary neutrophil gelatinase-associated lipocalin in patients with cirrhosis and acute kidney injury. Hepatology 77: 1630–1638, 2023 10.1002/hep.32799 PubMed

• PubMed
Gambino C, Piano S, Stenico M, Tonon M, Brocca A, Calvino V, : Diagnostic and prognostic performance of urinary neutrophil gelatinase-associated lipocalin in patients with cirrhosis and acute kidney injury. Hepatology 77: 1630–1638, 2023 10.1002/hep.32799 PubMed)| false
• Search Google Scholar
• Export Citation

Sohal A, Chaudhry H, Dukovic D, Kowdley KV: Outcomes among patients with hepatorenal syndrome based on hospital teaching and transplant status: Analysis of 159 845 hospitalizations. JGH Open 7: 848–854, 2023 10.1002/jgh3.12985 PubMed

• PubMed
Sohal A, Chaudhry H, Dukovic D, Kowdley KV: Outcomes among patients with hepatorenal syndrome based on hospital teaching and transplant status: Analysis of 159 845 hospitalizations. JGH Open 7: 848–854, 2023 10.1002/jgh3.12985 PubMed)| false
• Search Google Scholar
• Export Citation

Velez JCQ, Latt N, Rodby RA: Pathophysiology of hepatorenal syndrome. Adv Kidney Dis Health 31: 87–99, 2024 10.1053/j.akdh.2024.01.002 PubMed

• PubMed
Velez JCQ, Latt N, Rodby RA: Pathophysiology of hepatorenal syndrome. Adv Kidney Dis Health 31: 87–99, 2024 10.1053/j.akdh.2024.01.002 PubMed)| false
• Search Google Scholar
• Export Citation

Ring-Larsen H: Renal blood flow in cirrhosis: Relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest 37: 635–642, 1977 10.3109/00365517709100657 PubMed

• PubMed
Ring-Larsen H: Renal blood flow in cirrhosis: Relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest 37: 635–642, 1977 10.3109/00365517709100657 PubMed)| false
• Search Google Scholar
• Export Citation

Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J: Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8: 1151–1157, 1988 10.1002/hep.1840080532 PubMed

• PubMed
Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J: Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8: 1151–1157, 1988 10.1002/hep.1840080532 PubMed)| false
• Search Google Scholar
• Export Citation

Niederberger M, Martin PY, Ginès P, Morris K, Tsai P, Xu DL, et al.: Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 109: 1624–1630, 1995 10.1016/0016-5085(95)90652-5 PubMed

• PubMed
Niederberger M, Martin PY, Ginès P, Morris K, Tsai P, Xu DL, : Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 109: 1624–1630, 1995 10.1016/0016-5085(95)90652-5 PubMed)| false
• Search Google Scholar
• Export Citation

Stadlbauer V, Wright GAK, Banaji M, Mukhopadhya A, Mookerjee RP, Moore K, et al.: Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 134: 111–119, 2008 10.1053/j.gastro.2007.10.055 PubMed

• PubMed
Stadlbauer V, Wright GAK, Banaji M, Mukhopadhya A, Mookerjee RP, Moore K, : Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 134: 111–119, 2008 10.1053/j.gastro.2007.10.055 PubMed)| false
• Search Google Scholar
• Export Citation

Maoka T, Kawata T, Koike T, Mochizuki T, Schnermann J, Hashimoto S: Defective renal autoregulation in the chronic bile duct ligation model of liver failure. Clin Exp Nephrol 22: 1052–1060, 2018 10.1007/s10157-018-1551-9 PubMed

• PubMed
Maoka T, Kawata T, Koike T, Mochizuki T, Schnermann J, Hashimoto S: Defective renal autoregulation in the chronic bile duct ligation model of liver failure. Clin Exp Nephrol 22: 1052–1060, 2018 10.1007/s10157-018-1551-9 PubMed)| false
• Search Google Scholar
• Export Citation

Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, et al.: Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 146: 1680–1690 e1, 2014 10.1053/j.gastro.2014.03.005 PubMed

• PubMed
Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, : Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 146: 1680–1690 e1, 2014 10.1053/j.gastro.2014.03.005 PubMed)| false
• Search Google Scholar
• Export Citation

Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R: Prostaglandins: Modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 48: 895–900, 1979 10.1210/jcem-48-6-895 PubMed

• PubMed
Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R: Prostaglandins: Modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 48: 895–900, 1979 10.1210/jcem-48-6-895 PubMed)| false
• Search Google Scholar
• Export Citation

Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, et al.: Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 60: 940–947, 2014 10.1016/j.jhep.2013.12.019 PubMed

• PubMed
Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, : Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 60: 940–947, 2014 10.1016/j.jhep.2013.12.019 PubMed)| false
• Search Google Scholar
• Export Citation

Peng JL, Techasatian W, Hato T, Liangpunsakul S: Role of endotoxemia in causing renal dysfunction in cirrhosis. J Investig Med 68: 26–29, 2020 10.1136/jim-2019-001056 PubMed

• PubMed
Peng JL, Techasatian W, Hato T, Liangpunsakul S: Role of endotoxemia in causing renal dysfunction in cirrhosis. J Investig Med 68: 26–29, 2020 10.1136/jim-2019-001056 PubMed)| false
• Search Google Scholar
• Export Citation

Pak JM, Lee SS: Vasoactive effects of bile salts in cirrhotic rats: In vivo and in vitro studies. Hepatology 18: 1175–1181, 1993 10.1002/hep.1840180525 PubMed

• PubMed
Pak JM, Lee SS: Vasoactive effects of bile salts in cirrhotic rats: In vivo and in vitro studies. Hepatology 18: 1175–1181, 1993 10.1002/hep.1840180525 PubMed)| false
• Search Google Scholar
• Export Citation

Fickert P, Krones E, Pollheimer MJ, Thueringer A, Moustafa T, Silbert D, et al.: Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. Hepatology 58: 2056–2069, 2013 10.1002/hep.26599 PubMed

• PubMed
Fickert P, Krones E, Pollheimer MJ, Thueringer A, Moustafa T, Silbert D, : Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. Hepatology 58: 2056–2069, 2013 10.1002/hep.26599 PubMed)| false
• Search Google Scholar
• Export Citation

Ghallab A, González D, Strängberg E, Hofmann U, Myllys M, Hassan R, et al.: Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis. J Hepatol 80: 268–281, 2023 10.1016/j.jhep.2023.10.035 PubMed

• PubMed
Ghallab A, González D, Strängberg E, Hofmann U, Myllys M, Hassan R, : Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis. J Hepatol 80: 268–281, 2023 10.1016/j.jhep.2023.10.035 PubMed)| false
• Search Google Scholar
• Export Citation

Bräsen JH, Mederacke Y-S, Schmitz J, Diahovets K, Khalifa A, Hartleben B, et al.: Cholemic nephropathy causes acute kidney injury and is accompanied by loss of aquaporin 2 in collecting ducts. Hepatology 69: 2107–2119, 2019 10.1002/hep.30499 PubMed

• PubMed
Bräsen JH, Mederacke Y-S, Schmitz J, Diahovets K, Khalifa A, Hartleben B, : Cholemic nephropathy causes acute kidney injury and is accompanied by loss of aquaporin 2 in collecting ducts. Hepatology 69: 2107–2119, 2019 10.1002/hep.30499 PubMed)| false
• Search Google Scholar
• Export Citation

Seethapathy H, Sharma S, Zhao S, Chung RT, Connor MJ, Leaf DE, et al.: Acute kidney injury following paracentesis among inpatients with cirrhosis. Kidney Int Rep 5: 1305–1308, 2020 10.1016/j.ekir.2020.05.014 PubMed

• PubMed
Seethapathy H, Sharma S, Zhao S, Chung RT, Connor MJ, Leaf DE, : Acute kidney injury following paracentesis among inpatients with cirrhosis. Kidney Int Rep 5: 1305–1308, 2020 10.1016/j.ekir.2020.05.014 PubMed)| false
• Search Google Scholar
• Export Citation

Umgelter A, Reindl W, Franzen M, Lenhardt C, Huber W, Schmid RM: Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites. Intensive Care Med 35: 152–156, 2009 10.1007/s00134-008-1253-y PubMed

• PubMed
Umgelter A, Reindl W, Franzen M, Lenhardt C, Huber W, Schmid RM: Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites. Intensive Care Med 35: 152–156, 2009 10.1007/s00134-008-1253-y PubMed)| false
• Search Google Scholar
• Export Citation

Huggins JT, Doelken P, Walters C, Rockey DC: Point-of-care echocardiography improves assessment of volume status in cirrhosis and hepatorenal syndrome. Am J Med Scti 351: 550–553, 2016 10.1016/j.amjms.2016.02.040 PubMed

• PubMed
Huggins JT, Doelken P, Walters C, Rockey DC: Point-of-care echocardiography improves assessment of volume status in cirrhosis and hepatorenal syndrome. Am J Med Scti 351: 550–553, 2016 10.1016/j.amjms.2016.02.040 PubMed)| false
• Search Google Scholar
• Export Citation

Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al.: Diagnosis of portopulmonary hypertension in candidates for liver transplantation: A prospective study. Hepatology 37: 401–409, 2003 10.1053/jhep.2003.50060 PubMed

• PubMed
Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, : Diagnosis of portopulmonary hypertension in candidates for liver transplantation: A prospective study. Hepatology 37: 401–409, 2003 10.1053/jhep.2003.50060 PubMed)| false
• Search Google Scholar
• Export Citation

Gurghean AV, Tudor IA: Pulmonary hypertension in patients with hepatic cirrhosis and portal hypertension. An echographic study. Clujul Med 90: 161–165, 2017 10.15386/cjmed-705 PubMed

• PubMed
Gurghean AV, Tudor IA: Pulmonary hypertension in patients with hepatic cirrhosis and portal hypertension. An echographic study. Clujul Med 90: 161–165, 2017 10.15386/cjmed-705 PubMed)| false
• Search Google Scholar
• Export Citation

Li J, Zhuang Q, Zhang X, Zheng Y, Qiao Z, Zhang J, et al.: Prevalence and prognosis of portopulmonary hypertension in 223 liver transplant recipients. Can Respir J 2018: 9629570, 2018 10.1155/2018/9629570 PubMed

• PubMed
Li J, Zhuang Q, Zhang X, Zheng Y, Qiao Z, Zhang J, : Prevalence and prognosis of portopulmonary hypertension in 223 liver transplant recipients. Can Respir J 2018: 9629570, 2018 10.1155/2018/9629570 PubMed)| false
• Search Google Scholar
• Export Citation

Koratala A, Verbrugge F, Kazory A: Hepato-cardio-renal syndrome. Adv Kidney Dis Health 31: 127–132, 2024 10.1053/j.akdh.2023.07.002 PubMed

• PubMed
Koratala A, Verbrugge F, Kazory A: Hepato-cardio-renal syndrome. Adv Kidney Dis Health 31: 127–132, 2024 10.1053/j.akdh.2023.07.002 PubMed)| false
• Search Google Scholar
• Export Citation

Anikhindi SA, Ranjan P, Kumar M, Mohan R: A prospective study of prevalence and predictors of cirrhotic cardiomyopathy and its role in development of hepatorenal syndrome. J Clin Exp Hepatol 12: 853–860, 2022 10.1016/j.jceh.2021.11.005 PubMed

• PubMed
Anikhindi SA, Ranjan P, Kumar M, Mohan R: A prospective study of prevalence and predictors of cirrhotic cardiomyopathy and its role in development of hepatorenal syndrome. J Clin Exp Hepatol 12: 853–860, 2022 10.1016/j.jceh.2021.11.005 PubMed)| false
• Search Google Scholar
• Export Citation

Danielsen KV, Wiese S, Busk T, Nabilou P, Kronborg TM, Petersen CL, et al.: Cardiovascular mapping in cirrhosis from the compensated stage to hepatorenal syndrome: A magnetic resonance study. Am J Gastroenterol 117: 1269–1278, 2022 10.14309/ajg.0000000000001847 PubMed

• PubMed
Danielsen KV, Wiese S, Busk T, Nabilou P, Kronborg TM, Petersen CL, : Cardiovascular mapping in cirrhosis from the compensated stage to hepatorenal syndrome: A magnetic resonance study. Am J Gastroenterol 117: 1269–1278, 2022 10.14309/ajg.0000000000001847 PubMed)| false
• Search Google Scholar
• Export Citation

Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al.: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23: 164–176, 1996 10.1002/hep.510230122 PubMed

• PubMed
Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, : Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23: 164–176, 1996 10.1002/hep.510230122 PubMed)| false
• Search Google Scholar
• Export Citation

Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al.: Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. J Hepatol 62: 968–974, 2015 10.1016/j.jhep.2014.12.029 PubMed

• PubMed
Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A, : Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. J Hepatol 62: 968–974, 2015 10.1016/j.jhep.2014.12.029 PubMed)| false
• Search Google Scholar
• Export Citation

Nadim MK, Kellum JA, Forni L, Francoz C, Asrani SK, Ostermann M, et al.: Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. J Hepatol 81: 163–183, 2024 10.1016/j.jhep.2024.03.031 PubMed

• PubMed
Nadim MK, Kellum JA, Forni L, Francoz C, Asrani SK, Ostermann M, : Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. J Hepatol 81: 163–183, 2024 10.1016/j.jhep.2024.03.031 PubMed)| false
• Search Google Scholar
• Export Citation

Amathieu R, Al-Khafaji A, Sileanu FE, Foldes E, DeSensi R, Hilmi I, et al.: Significance of oliguria in critically ill patients with chronic liver disease. Hepatology 66: 1592–1600, 2017 10.1002/hep.29303 PubMed

• PubMed
Amathieu R, Al-Khafaji A, Sileanu FE, Foldes E, DeSensi R, Hilmi I, : Significance of oliguria in critically ill patients with chronic liver disease. Hepatology 66: 1592–1600, 2017 10.1002/hep.29303 PubMed)| false
• Search Google Scholar
• Export Citation

Premkumar M, Rangegowda D, Kajal K, Khumuckham JS: Noninvasive estimation of intravascular volume status in cirrhosis by dynamic size and collapsibility indices of the inferior vena cava using bedside echocardiography. JGH Open 3: 322–328, 2019 10.1002/jgh3.12166 PubMed

• PubMed
Premkumar M, Rangegowda D, Kajal K, Khumuckham JS: Noninvasive estimation of intravascular volume status in cirrhosis by dynamic size and collapsibility indices of the inferior vena cava using bedside echocardiography. JGH Open 3: 322–328, 2019 10.1002/jgh3.12166 PubMed)| false
• Search Google Scholar
• Export Citation

Velez JCQ, Petkovich B, Karakala N, Huggins JT: Point-of-care echocardiography unveils misclassification of acute kidney injury as hepatorenal syndrome. Am J Nephrol 50: 204–211, 2019 10.1159/000501299 PubMed

• PubMed
Velez JCQ, Petkovich B, Karakala N, Huggins JT: Point-of-care echocardiography unveils misclassification of acute kidney injury as hepatorenal syndrome. Am J Nephrol 50: 204–211, 2019 10.1159/000501299 PubMed)| false
• Search Google Scholar
• Export Citation

China L, Freemantle N, Forrest E, Kallis Y, Ryder SD, Wright G, ATTIRE Trial Investigators, et al.: A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med 384: 808–817, 2021 10.1056/NEJMoa2022166 PubMed

• PubMed
China L, Freemantle N, Forrest E, Kallis Y, Ryder SD, Wright G, ATTIRE Trial Investigators, : A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med 384: 808–817, 2021 10.1056/NEJMoa2022166 PubMed)| false
• Search Google Scholar
• Export Citation

Velez JCQ, Therapondos G, Juncos LA: Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol 16: 137–155, 2020 10.1038/s41581-019-0218-4 PubMed

• PubMed
Velez JCQ, Therapondos G, Juncos LA: Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol 16: 137–155, 2020 10.1038/s41581-019-0218-4 PubMed)| false
• Search Google Scholar
• Export Citation

Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al.: Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Hepatology 20: 1495–1501, 1994 10.1002/hep.1840200619 PubMed

• PubMed
Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, : Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Hepatology 20: 1495–1501, 1994 10.1002/hep.1840200619 PubMed)| false
• Search Google Scholar
• Export Citation

Ubhi N, Mourad A, Tausan M, Lewis D, Smethurst J, Wenlock R, et al.: Outcomes after hospitalisation with spontaneous bacterial peritonitis over a 13-year period: A retrospective cohort study. Eur J Gastroenterol Hepatol 35: 384–393, 2023 10.1097/MEG.0000000000002524 PubMed

• PubMed
Ubhi N, Mourad A, Tausan M, Lewis D, Smethurst J, Wenlock R, : Outcomes after hospitalisation with spontaneous bacterial peritonitis over a 13-year period: A retrospective cohort study. Eur J Gastroenterol Hepatol 35: 384–393, 2023 10.1097/MEG.0000000000002524 PubMed)| false
• Search Google Scholar
• Export Citation

Alsaad AA, Wadei HM: Fractional excretion of sodium in hepatorenal syndrome: Clinical and pathological correlation. World J Hepatol 8: 1497–1501, 2016 10.4254/wjh.v8.i34.1497 PubMed

• PubMed
Alsaad AA, Wadei HM: Fractional excretion of sodium in hepatorenal syndrome: Clinical and pathological correlation. World J Hepatol 8: 1497–1501, 2016 10.4254/wjh.v8.i34.1497 PubMed)| false
• Search Google Scholar
• Export Citation

Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, TRIBE-AKI Consortium, et al.: Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 60: 622–632, 2014 10.1002/hep.26980 PubMed

• PubMed
Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, TRIBE-AKI Consortium, : Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 60: 622–632, 2014 10.1002/hep.26980 PubMed)| false
• Search Google Scholar
• Export Citation

Gowda YHS, Jagtap N, Karyampudi A, Rao NP, Deepika G, Sharma M, et al.: Fractional excretion of sodium and urea in differentiating acute kidney injury phenotypes in decompensated cirrhosis. J Clin Exp Hepatol 12: 899–907, 2022 10.1016/j.jceh.2021.09.019 PubMed

• PubMed
Gowda YHS, Jagtap N, Karyampudi A, Rao NP, Deepika G, Sharma M, : Fractional excretion of sodium and urea in differentiating acute kidney injury phenotypes in decompensated cirrhosis. J Clin Exp Hepatol 12: 899–907, 2022 10.1016/j.jceh.2021.09.019 PubMed)| false
• Search Google Scholar
• Export Citation

Allegretti AS, Parada XV, Endres P, Zhao S, Krinsky S, St Hillien SA, HRS-HARMONY study investigators, et al.: Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis: A prospective study. Clin Transl Gastroenterol 12: e00359, 2021 10.14309/ctg.0000000000000359 PubMed

• PubMed
Allegretti AS, Parada XV, Endres P, Zhao S, Krinsky S, St Hillien SA, HRS-HARMONY study investigators, : Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis: A prospective study. Clin Transl Gastroenterol 12: e00359, 2021 10.14309/ctg.0000000000000359 PubMed)| false
• Search Google Scholar
• Export Citation

Watany MM, Hagag RY, Okda HI: Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: A pilot study. Clin Chem Lab Med 56: 739–747, 2018 10.1515/cclm-2017-0483 PubMed

• PubMed
Watany MM, Hagag RY, Okda HI: Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: A pilot study. Clin Chem Lab Med 56: 739–747, 2018 10.1515/cclm-2017-0483 PubMed)| false
• Search Google Scholar
• Export Citation

Allegretti AS, Ortiz G, Wenger J, Deferio JJ, Wibecan J, Kalim S, et al.: Prognosis of acute kidney injury and hepatorenal syndrome in patients with cirrhosis: A prospective cohort study. Int J Nephrol 2015: 108139, 2015 10.1155/2015/108139 PubMed

• PubMed
Allegretti AS, Ortiz G, Wenger J, Deferio JJ, Wibecan J, Kalim S, : Prognosis of acute kidney injury and hepatorenal syndrome in patients with cirrhosis: A prospective cohort study. Int J Nephrol 2015: 108139, 2015 10.1155/2015/108139 PubMed)| false
• Search Google Scholar
• Export Citation

Varghese V, Rivera MS, Alalwan A, Alghamdi AM, Ramanand A, Khan SM, et al.: Concomitant identification of muddy brown granular casts and low fractional excretion of urinary sodium in AKI. Kidney360 3: 627–635, 2022 10.34067/KID.0005692021 PubMed

• PubMed
Varghese V, Rivera MS, Alalwan A, Alghamdi AM, Ramanand A, Khan SM, : Concomitant identification of muddy brown granular casts and low fractional excretion of urinary sodium in AKI. Kidney360 3: 627–635, 2022 10.34067/KID.0005692021 PubMed)| false
• Search Google Scholar
• Export Citation

Poloni JAT, Perazella MA, Keitel E, Marroni CA, Leite SB, Rotta LN: Utility of a urine sediment score in hyperbilirubinemia/hyperbilirubinuria. Clin Nephrol 92: 141–150, 2019 10.5414/CN109673 PubMed

• PubMed
Poloni JAT, Perazella MA, Keitel E, Marroni CA, Leite SB, Rotta LN: Utility of a urine sediment score in hyperbilirubinemia/hyperbilirubinuria. Clin Nephrol 92: 141–150, 2019 10.5414/CN109673 PubMed)| false
• Search Google Scholar
• Export Citation

Scilletta S, Leggio S, Di Marco M, Miano N, Musmeci M, Marrano N, et al.: Acute hyperbilirubinemia determines an early subclinical renal damage: Evaluation of tubular biomarkers in cholemic nephropathy. Liver Int, 2024 10.1111/liv.16005 PubMed

• PubMed
Scilletta S, Leggio S, Di Marco M, Miano N, Musmeci M, Marrano N, : Acute hyperbilirubinemia determines an early subclinical renal damage: Evaluation of tubular biomarkers in cholemic nephropathy. Liver Int, 2024 10.1111/liv.16005 PubMed)| false
• Search Google Scholar
• Export Citation

Ma AT, Solé C, Juanola A, Escudé L, Napoleone L, Avitabile E, et al.: Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis. J Hepatol, 2024 10.1016/j.jhep.2024.03.006 PubMed

• PubMed
Ma AT, Solé C, Juanola A, Escudé L, Napoleone L, Avitabile E, : Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis. J Hepatol, 2024 10.1016/j.jhep.2024.03.006 PubMed)| false
• Search Google Scholar
• Export Citation

Kastelan S, Ljubicic N, Kastelan Z, Ostojic R, Uravic M: The role of duplex-Doppler ultrasonography in the diagnosis of renal dysfunction and hepatorenal syndrome in patients with liver cirrhosis. Hepatogastroenterology 51: 1408–1412, 2004 PubMed

• PubMed
Kastelan S, Ljubicic N, Kastelan Z, Ostojic R, Uravic M: The role of duplex-Doppler ultrasonography in the diagnosis of renal dysfunction and hepatorenal syndrome in patients with liver cirrhosis. Hepatogastroenterology 51: 1408–1412, 2004 PubMed)| false
• Search Google Scholar
• Export Citation

Saad M, Ellis CL, O’Neill WC: Renal hypertrophy in liver failure. Kidney Int Rep 3: 1464–1467, 2018 10.1016/j.ekir.2018.07.004

• PubMed
Saad M, Ellis CL, O’Neill WC: Renal hypertrophy in liver failure. Kidney Int Rep 3: 1464–1467, 2018 10.1016/j.ekir.2018.07.004)| false
• Search Google Scholar
• Export Citation

Cullaro G, Kanduri SR, Velez JCQ: Acute kidney injury in patients with liver disease. Clin J Am Soc Nephrol 17: 1674–1684, 2022 10.2215/CJN.03040322 PubMed

• PubMed
Cullaro G, Kanduri SR, Velez JCQ: Acute kidney injury in patients with liver disease. Clin J Am Soc Nephrol 17: 1674–1684, 2022 10.2215/CJN.03040322 PubMed)| false
• Search Google Scholar
• Export Citation

Kanduri SR, Peleg Y, Wadhwani S: Liver disease-associated glomerulopathies. Adv Kidney Dis Health 31: 147–156, 2024 10.1053/j.akdh.2023.11.002 PubMed

• PubMed
Kanduri SR, Peleg Y, Wadhwani S: Liver disease-associated glomerulopathies. Adv Kidney Dis Health 31: 147–156, 2024 10.1053/j.akdh.2023.11.002 PubMed)| false
• Search Google Scholar
• Export Citation

Vaidyanathan S, Soni BM, Hughes PL: Midodrine: Insidious development of urologic adverse effects in patients with spinal cord injury: A report of 2 cases. Adv Ther 24: 712–720, 2007 10.1007/BF02849965 PubMed

• PubMed
Vaidyanathan S, Soni BM, Hughes PL: Midodrine: Insidious development of urologic adverse effects in patients with spinal cord injury: A report of 2 cases. Adv Ther 24: 712–720, 2007 10.1007/BF02849965 PubMed)| false
• Search Google Scholar
• Export Citation

Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al.: Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29: 1690–1697, 1999 10.1002/hep.510290629 PubMed

• PubMed
Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, : Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29: 1690–1697, 1999 10.1002/hep.510290629 PubMed)| false
• Search Google Scholar
• Export Citation

Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA: Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 52: 742–748, 2007 10.1007/s10620-006-9312-0 PubMed

• PubMed
Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA: Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 52: 742–748, 2007 10.1007/s10620-006-9312-0 PubMed)| false
• Search Google Scholar
• Export Citation

Lenz K, Hörtnagl H, Druml W, Reither H, Schmid R, Schneeweiss B, et al.: Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 101: 1060–1067, 1991 10.1016/0016-5085(91)90734-3 PubMed

• PubMed
Lenz K, Hörtnagl H, Druml W, Reither H, Schmid R, Schneeweiss B, : Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 101: 1060–1067, 1991 10.1016/0016-5085(91)90734-3 PubMed)| false
• Search Google Scholar
• Export Citation

Kew MC, Varma RR, Sampson DJ, Sherlock S: The effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liver. Gut 13: 293–296, 1972 10.1136/gut.13.4.293 PubMed

• PubMed
Kew MC, Varma RR, Sampson DJ, Sherlock S: The effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liver. Gut 13: 293–296, 1972 10.1136/gut.13.4.293 PubMed)| false
• Search Google Scholar
• Export Citation

Hirasawa A, Shibata K, Kotosai K, Tsujimoto G: Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun 203: 72–79, 1994 10.1006/bbrc.1994.2150 PubMed

• PubMed
Hirasawa A, Shibata K, Kotosai K, Tsujimoto G: Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun 203: 72–79, 1994 10.1006/bbrc.1994.2150 PubMed)| false
• Search Google Scholar
• Export Citation

Martín-Llahí M, Pépin M-N, Guevara M, Díaz F, Torre A, Monescillo A, TAHRS Investigators, et al.: Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: A randomized study. Gastroenterology 134: 1352–1359, 2008 10.1053/j.gastro.2008.02.024 PubMed

• PubMed
Martín-Llahí M, Pépin M-N, Guevara M, Díaz F, Torre A, Monescillo A, TAHRS Investigators, : Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: A randomized study. Gastroenterology 134: 1352–1359, 2008 10.1053/j.gastro.2008.02.024 PubMed)| false
• Search Google Scholar
• Export Citation

Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, et al.: Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 53: 830–835, 2008 10.1007/s10620-007-9919-9 PubMed

• PubMed
Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, : Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 53: 830–835, 2008 10.1007/s10620-007-9919-9 PubMed)| false
• Search Google Scholar
• Export Citation

Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK: Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18: 152–156, 2003 10.1046/j.1440-1746.2003.02934.x PubMed

• PubMed
Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK: Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18: 152–156, 2003 10.1046/j.1440-1746.2003.02934.x PubMed)| false
• Search Google Scholar
• Export Citation

Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, et al.: Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: Results of a multicentre pilot study. Eur J Gastroenterol Hepatol 14: 153–158, 2002 10.1097/00042737-200202000-00009 PubMed

• PubMed
Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, : Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: Results of a multicentre pilot study. Eur J Gastroenterol Hepatol 14: 153–158, 2002 10.1097/00042737-200202000-00009 PubMed)| false
• Search Google Scholar
• Export Citation

Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, et al.: Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: A pilot study. Acta Gastroenterol Belg 64: 15–19, 2001 PubMed

• PubMed
Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, : Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: A pilot study. Acta Gastroenterol Belg 64: 15–19, 2001 PubMed)| false
• Search Google Scholar
• Export Citation

Muñoz LE, Alcalá EG, Cordero P, Martinez MA, Vázquez NY, Galindo S, et al.: Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico. Ann Hepatol 8: 207–211, 2009 10.1016/S1665-2681(19)31767-3 PubMed

• PubMed
Muñoz LE, Alcalá EG, Cordero P, Martinez MA, Vázquez NY, Galindo S, : Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico. Ann Hepatol 8: 207–211, 2009 10.1016/S1665-2681(19)31767-3 PubMed)| false
• Search Google Scholar
• Export Citation

Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Terlipressin Study Group, et al.: A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134: 1360–1368, May 2008 10.1053/j.gastro.2008.02.014 PubMed

• PubMed
Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Terlipressin Study Group, : A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134: 1360–1368, May 2008 10.1053/j.gastro.2008.02.014 PubMed)| false
• Search Google Scholar
• Export Citation

Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O’Leary JG, REVERSE Study Investigators, et al.: Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology 150: 1579–1589 e2, 2016 10.1053/j.gastro.2016.02.026 PubMed

• PubMed
Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O’Leary JG, REVERSE Study Investigators, : Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology 150: 1579–1589 e2, 2016 10.1053/j.gastro.2016.02.026 PubMed)| false
• Search Google Scholar
• Export Citation

Wong F, Pappas SC, Curry MP, Reddy KR, Rubin RA, Porayko MK, CONFIRM Study Investigators, et al.: Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med 384: 818–828, 2021 10.1056/NEJMoa2008290 PubMed

• PubMed
Wong F, Pappas SC, Curry MP, Reddy KR, Rubin RA, Porayko MK, CONFIRM Study Investigators, : Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med 384: 818–828, 2021 10.1056/NEJMoa2008290 PubMed)| false
• Search Google Scholar
• Export Citation

Velez JCQ, Wong F, Reddy KR, Sanyal AJ, Vargas HE, Curry MP, et al.: The effect of terlipressin on renal replacement therapy in patients with hepatorenal wyndrome. Kidney360 4: 1030–1038, 2023 10.34067/KID.0000000000000132 PubMed

• PubMed
Velez JCQ, Wong F, Reddy KR, Sanyal AJ, Vargas HE, Curry MP, : The effect of terlipressin on renal replacement therapy in patients with hepatorenal wyndrome. Kidney360 4: 1030–1038, 2023 10.34067/KID.0000000000000132 PubMed)| false
• Search Google Scholar
• Export Citation

Pichler RH, Swenson ER, Leary PJ, Paine CH: Terlipressin: Hopes fulfilled or dashed? Clin J Am Soc Nephrol 17: 140–142, 2022 10.2215/CJN.06710521 PubMed

• PubMed
Pichler RH, Swenson ER, Leary PJ, Paine CH: Terlipressin: Hopes fulfilled or dashed? Clin J Am Soc Nephrol 17: 140–142, 2022 10.2215/CJN.06710521 PubMed)| false
• Search Google Scholar
• Export Citation

Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, et al.: Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology 63: 983–992, 2016 10.1002/hep.28396 PubMed

• PubMed
Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, : Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology 63: 983–992, 2016 10.1002/hep.28396 PubMed)| false
• Search Google Scholar
• Export Citation

Duvoux C, Zanditenas D, Hézode C, Chauvat A, Monin J-L, Roudot-Thoraval F, et al.: Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study. Hepatology 36: 374–380, 2002 10.1053/jhep.2002.34343 PubMed

• PubMed
Duvoux C, Zanditenas D, Hézode C, Chauvat A, Monin J-L, Roudot-Thoraval F, : Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study. Hepatology 36: 374–380, 2002 10.1053/jhep.2002.34343 PubMed)| false
• Search Google Scholar
• Export Citation

Sharma P, Kumar A, Shrama BC, Sarin SK: An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 103: 1689–1697, 2008 10.1111/j.1572-0241.2008.01828.x Comparative Study Randomized Controlled Trial. PubMed

• PubMed
Sharma P, Kumar A, Shrama BC, Sarin SK: An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 103: 1689–1697, 2008 10.1111/j.1572-0241.2008.01828.x Comparative Study Randomized Controlled Trial. PubMed)| false
• Search Google Scholar
• Export Citation

Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al.: Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: A randomized study. J Hepatol 56: 1293–1298, 2012 10.1016/j.jhep.2012.01.012 PubMed

• PubMed
Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, : Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: A randomized study. J Hepatol 56: 1293–1298, 2012 10.1016/j.jhep.2012.01.012 PubMed)| false
• Search Google Scholar
• Export Citation

Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA: Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study. Indian J Gastroenterol 37: 424–429, 2018 10.1007/s12664-018-0876-3 PubMed

• PubMed
Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA: Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study. Indian J Gastroenterol 37: 424–429, 2018 10.1007/s12664-018-0876-3 PubMed)| false
• Search Google Scholar
• Export Citation

Badawy SS, M N, Ahmed A: Norepinephrine versus terlipressin in patients with type 1 hepatorenal syndrome refractory to treatment with octreotide, midodrine, and albumin: A prospective randomized comparative study. Egypt J Cardiothorac Anesth 7: 13–18, 2013

• PubMed
Badawy SS, M N, Ahmed A: Norepinephrine versus terlipressin in patients with type 1 hepatorenal syndrome refractory to treatment with octreotide, midodrine, and albumin: A prospective randomized comparative study. Egypt J Cardiothorac Anesth 7: 13–18, 2013)| false
• Search Google Scholar
• Export Citation

Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, et al.: Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study. J Hepatol 47: 499–505, 2007 10.1016/j.jhep.2007.04.010 PubMed

• PubMed
Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, : Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study. J Hepatol 47: 499–505, 2007 10.1016/j.jhep.2007.04.010 PubMed)| false
• Search Google Scholar
• Export Citation

Goyal O, Sidhu SS, Sehgal N, Puri S: Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: A prospective, randomized trial. J Assoc Physicians India 64: 30–35, 2016 PubMed

• PubMed
Goyal O, Sidhu SS, Sehgal N, Puri S: Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: A prospective, randomized trial. J Assoc Physicians India 64: 30–35, 2016 PubMed)| false
• Search Google Scholar
• Export Citation

Malik A, Malik MI, Qureshi S, Nadir A: Efficacy and safety of terlipressin and albumin vs. noradrenaline and albumin in adult patients with hepatorenal syndrome: A systematic review and meta-analysis. Ann Hepatol 29: 101495, 2024 10.1016/j.aohep.2024.101495 PubMed